Yıl: 2022 Cilt: 48 Sayı: 1 Sayfa Aralığı: 58 - 63 Metin Dili: İngilizce DOI: 10.5152/tud.2022.21276 İndeks Tarihi: 16-06-2022

Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma

Öz:
Objective: Renal cancer is the most lethal among urological cancer. Treatments of renal cell carcinoma (RCC) may be possible by immune checkpoint inhibitors and drug treatment targeting different molecules. We aimed to determine the apoptotic effect of betulinic acid and its effects on expressions of apoptosisassociated genes AKT-1 and mTOR in RCC cells. Material and methods: In this study, we investigated the apoptotic activity of betulinic acid in CAKI-2 cell line and its effect on AKT-1 and mTOR gene expression levels. In order to do so, following analyses were conducted: WST-1 to identify the toxic effect of betulinic acid, Caspase-3/BCA to detect caspase enzyme activity, Annexin-V and ELISA to determine for apoptotic effect, and finally, real-time PCR for expression levels of AKT-1 and mTOR. Results: Our study showed that different concentrations of betulinic acid induced apoptosis in renal cancer; however, no effect was observed in healthy cells. In gene expression analysis, there was statistically significant decrease in AKT-1 expression level while increasing mTOR expression level. Conclusion: We suggested that betulinic acid with its apoptotic effect on RCC line and nontoxic effect on healthy cell line and the effects on AKT/mTOR pathway may be a potential anticancer drug promising for future studies.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74-84. [CrossRef]
  • 2. Linehan WM, Ricketts CJ. The metabolic basis of kidney cancer. Semin Cancer Biol. 2013;23(1):46-55. [CrossRef]
  • 3. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894-906. [CrossRef]
  • 4. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009. [CrossRef]
  • 5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [CrossRef]
  • 6. Zaman S, Wang R, Gandhi V. Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma. 2014;55(9):1980- 1992. [CrossRef]
  • 7. Sa´nchez-Gastaldo A, Kempf E, Gonza´lez del Alba A, Duran I. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 2017;60:77-89. [CrossRef
  • 8. Guo H, German P, Bai S, et al. The PI3K/AKT pathway and renal cell carcinoma. J Genet Genomics. 2015;42(7):343-353. [Cross- Ref]
  • 9. Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol BioSyst. 2015;11(7):1946-1954. [CrossRef]
  • 10. O’Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKTmTOR inhibition in cancer immunotherapy redux. Semin Cancer Biol. 2018;48:91-103. [CrossRef]
  • 11. Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs. 2009;20(10):880-892. [CrossRef]
  • 12. Zhou M, Zhang RH, Wang M, Xu GB, Liao SG. Prodrugs of triterpenoids and their derivatives. Eur J Med Chem. 2017;131:222- 236. [CrossRef]
  • 13. Ren Y, Kinghorn A. Natural product triterpenoids and their semisynthetic derivatives with potential anticancer activity. Planta Med. 2019;85(11-12):802-814. [CrossRef]
  • 14. Xu F, Huang X, Wu H, Wang X. Beneficial health effects of lupenone triterpene: A review. Biomed Pharmacother. 2018;103:198- 203. [CrossRef]
  • 15. Castro MJ, Careaga VP, Sacca PA, Faraoni MB, Murray AP, Calvo JC. Lupane triterpenoids and new derivatives as antiproliferative agents against prostate cancer cells. Anticancer Res. 2019;39(7):3835-3845. [CrossRef]
  • 16. Sun Y, Gao LL, Tang MY, Feng BM, Pei YH, Yasukawa K. Triterpenoids from euphorbia maculata and their anti-inflammatory effects. Molecules. 2018;23(9):2112. [CrossRef]
  • 17. Khwaza V, Oyedeji OO, Aderibigbe BA. Antiviral activities of oleanolic acid and its analogues. Molecules. 2018;23(9):2300. [CrossRef]
  • 18. Yu JH, Yu ZP, Wang YY, et al. Triterpenoids and triterpenoid saponins from dipsacus asper and their cytotoxic and antibacterial activities. Phytochemistry. 2019;162:241-249. [CrossRef]
  • 19. Chudzik M, Korzonek-Szlacheta I, Kro´l W. Triterpenes as potentially cytotoxic compounds. Molecules. 2015;20(1):1610-1625. [CrossRef]
  • 20. Fulda S, Scaffidi C, Susin SA, et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem. 1998;273(51):33942-33948. [CrossRef]
  • 21. Potze L, Mullauer FB, Colak S, Kessler JH, Medema JP. Betulinic acid-induced mitochondria-dependent cell death is counterbalanced by an autophagic salvage response. Cell Death Dis. 2014;5:E1169-E1169. [CrossRef]
  • 22. Lee D, Lee SR, Kang KS, et al. Betulinic acid suppresses ovarian cancer cell proliferation through induction of apoptosis. Biomolecules. 2019;9(7):57.
  • 23. Wang W, Wang Y, Liu M, et al. Betulinic acid induces apoptosis and suppresses metastasis in hepatocellular carcinoma cell lines in vitro and in vivo. J Cell Mol Med. 2019;23(1):586-595. [CrossRef]
  • 24. Zeng A, Hua H, Liu L, Zhao J. Betulinic acid induces apoptosis and inhibits metastasis of human colorectal cancer cells in vitro and in vivo. Bioorg Med Chem March. 2019;27(12):2546-2552. [CrossRef]
  • 25. Amiri S, Dastghaib S, Ahmadi M, et al. Betulin and its derivatives as novel compounds with different pharmacological effects. Biotechnol Adv. 2019;38:107409.
  • 26. Kumar P, Bhadauria AS, Singh AK, Saha S. Betulinic acid as apoptosis activator: Molecular mechanisms, mathematical modeling and chemical modifications. Life Sci. 2018;209:24-33. [CrossRef]
  • 27. Shankar E, Zhang A, Franco D, et al. Betulinic acid-mediated apoptosis in human prostate cancer cells involves p53 and nuclear factor-kappa B (NF-jB) pathways. Molecules. 2017;22(2):264. [CrossRef]
  • 28. Xu T, Pang Q, Wang Y, Yan X. Betulinic acid induces apoptosis by regulating PI3K/Akt signaling and mitochondrial pathways in human cervical cancer cells. Int J Mol Med. 2017;40(6):1669- 1678. [CrossRef]
  • 29. Pandey MK, Sung B, Aggarwal BB. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer. 2010;127(2):282-292. [CrossRef]
APA ATAS M, Ertugrul B, Bireller S, Cakmakoglu B, ergen a (2022). Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. , 58 - 63. 10.5152/tud.2022.21276
Chicago ATAS MERVE NUR,Ertugrul Baris,Bireller Sinem,Cakmakoglu Bedia,ergen arzu Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. (2022): 58 - 63. 10.5152/tud.2022.21276
MLA ATAS MERVE NUR,Ertugrul Baris,Bireller Sinem,Cakmakoglu Bedia,ergen arzu Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. , 2022, ss.58 - 63. 10.5152/tud.2022.21276
AMA ATAS M,Ertugrul B,Bireller S,Cakmakoglu B,ergen a Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. . 2022; 58 - 63. 10.5152/tud.2022.21276
Vancouver ATAS M,Ertugrul B,Bireller S,Cakmakoglu B,ergen a Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. . 2022; 58 - 63. 10.5152/tud.2022.21276
IEEE ATAS M,Ertugrul B,Bireller S,Cakmakoglu B,ergen a "Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma." , ss.58 - 63, 2022. 10.5152/tud.2022.21276
ISNAD ATAS, MERVE NUR vd. "Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma". (2022), 58-63. https://doi.org/10.5152/tud.2022.21276
APA ATAS M, Ertugrul B, Bireller S, Cakmakoglu B, ergen a (2022). Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. Turkish Journal of Urology, 48(1), 58 - 63. 10.5152/tud.2022.21276
Chicago ATAS MERVE NUR,Ertugrul Baris,Bireller Sinem,Cakmakoglu Bedia,ergen arzu Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. Turkish Journal of Urology 48, no.1 (2022): 58 - 63. 10.5152/tud.2022.21276
MLA ATAS MERVE NUR,Ertugrul Baris,Bireller Sinem,Cakmakoglu Bedia,ergen arzu Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. Turkish Journal of Urology, vol.48, no.1, 2022, ss.58 - 63. 10.5152/tud.2022.21276
AMA ATAS M,Ertugrul B,Bireller S,Cakmakoglu B,ergen a Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. Turkish Journal of Urology. 2022; 48(1): 58 - 63. 10.5152/tud.2022.21276
Vancouver ATAS M,Ertugrul B,Bireller S,Cakmakoglu B,ergen a Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. Turkish Journal of Urology. 2022; 48(1): 58 - 63. 10.5152/tud.2022.21276
IEEE ATAS M,Ertugrul B,Bireller S,Cakmakoglu B,ergen a "Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma." Turkish Journal of Urology, 48, ss.58 - 63, 2022. 10.5152/tud.2022.21276
ISNAD ATAS, MERVE NUR vd. "Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma". Turkish Journal of Urology 48/1 (2022), 58-63. https://doi.org/10.5152/tud.2022.21276